3.1 Diabetic nephropathy Globally, approximately 40% of individuals with diabetes are at risk of developing CKD, revealing a close association between these two conditions
Randomisation via an interactive web-response system was 1:1:1:3 to a once-weekly subcutaneous injection of tirzepatide (5mg, 10mg, or 15mg) or a once-daily subcutaneous injection of titrated insulin glargine (100U/mL)
Following the first four weeks, dosages may be raised once weekly by 2.5 mg increments, if tolerated, up to a maximum of 15 mg
The weight benefit is also complementary
It also helps your pancreas release the right amount of insulin when your blood sugar rises
The treatment group had lower LDL cholesterol values compared with the placebo group